The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in healthy male volunteers.
To evaluate the pharmacokinetic Interaction, safety and tolerability of the combination compared with the administration of AD-2071 and AD-2072.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
38
AD-2071 10/20 mg tablet
AD-2072 80/5mg tablet
AD-2071 10/20 mg + AD-2072 80/5mg tablet
Seoul National University Hospital
Seoul, South Korea
Peak Plasma Concentration
Cmax of the total ingredient of AD-2071 and AD-2072
Time frame: pre-dose to 24 hours
Area under the plasma concentration versus time curve
AUCtau of the total ingredient of AD-2071 and AD-20172
Time frame: pre-dose to 24 hours
Time to reach Cmax
Tmax of the total ingredient of AD-2071 and AD-2072
Time frame: pre-dose to 24 hours
Elimination half-life
t1/2 of the total ingredient of AD-2071 and AD-2072
Time frame: pre-dose to 24 hours
Clearance
CL/F of the total ingredient of AD-2071 and AD-2072
Time frame: pre-dose to 24 hours
Volume of distribution
Vd/F of the total ingredient of AD-2071 and AD-2072
Time frame: pre-dose to 24 hours
Number of participants with adverse events
Incidence rate of adverse events
Time frame: From Day 1 up to Day 46
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.